OncoZenge AB (OSTO:ONCOZ) Beta: 1.2892 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ONCOZ OncoZenge AB OSTO:ONCOZ
26 GF Score
Price kr7.49
! 2 Warning Signs
View Full Analysis

What is OncoZenge AB Beta?

OncoZenge AB OSTO:ONCOZ +4.03% 26 Beta is 1.2892 as of Jul. 22, 2026. GuruFocus rates OSTO:ONCOZ with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-22), OncoZenge AB's Beta is 1.2892.


OncoZenge AB  (OSTO:ONCOZ) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


OncoZenge AB Beta Related Terms


OncoZenge AB Beta Historical Data

* Premium members only.

The historical data trend for OncoZenge AB's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoZenge AB Beta Chart

OncoZenge AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 1.00 1.64

OncoZenge AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.25 1.38 1.80 1.64 1.47

OSTO:ONCOZ vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, OncoZenge AB's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoZenge AB Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoZenge AB's Beta distribution charts can be found below:

* The bar in red indicates where OncoZenge AB's Beta falls into.


OSTO:ONCOZ
26GF Score
OncoZenge AB OSTO:ONCOZ
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoZenge AB Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.2892 mean?
OncoZenge AB (OSTO:ONCOZ) has a Beta of 1.2892 as of Jul. 22, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for OncoZenge AB and its competitors.
Is OncoZenge AB's Beta too high?
OncoZenge AB's current Beta is 1.2892. Overall, OncoZenge AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does OncoZenge AB's Beta compare to VRTX and REGN?
OncoZenge AB's Beta of 1.2892 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for OncoZenge AB and its competitors. OncoZenge AB's current Beta is 1.2892. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoZenge AB stock overvalued right now?
OncoZenge AB (OSTO:ONCOZ) has a current Beta of 1.2892. The current Beta is 1.2892. OncoZenge AB's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For OncoZenge AB (OSTO:ONCOZ), the current Beta is 1.2892 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoZenge AB Business Description

Address Gustavslundsvagen 34, Bromma, SWE, 167 51
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
26GF Score

Get the complete analysis for OSTO:ONCOZ

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr7.49
Price